A citation-based method for searching scientific literature

Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm, Lilian Wikström. J Neurosci Res 2008
Times Cited: 240







List of co-cited articles
1479 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
339
63

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
405
58

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
278
48

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
190
47


Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
160
40



In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht,[...]. Front Aging Neurosci 2016
204
28

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
467
28

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
589
28

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.
Seung Pil Yun, Tae-In Kam, Nikhil Panicker, SangMin Kim, Yumin Oh, Jong-Sung Park, Seung-Hwan Kwon, Yong Joo Park, Senthilkumar S Karuppagounder, Hyejin Park,[...]. Nat Med 2018
412
25

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Simon C Cork, James E Richards, Marie K Holt, Fiona M Gribble, Frank Reimann, Stefan Trapp. Mol Metab 2015
221
24


GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
Yazhou Li, Kara B Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A Bailey, Harold W Holloway, David Tweedie, Tracyann Perry, Mark P Mattson, Dimitrios Kapogiannis,[...]. J Alzheimers Dis 2010
229
23

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
TracyAnn Perry, Debomoy K Lahiri, Demao Chen, Jie Zhou, Karen T Y Shaw, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
233
22

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Ziyue Yuan, Dongfang Li, Peng Feng, Guofang Xue, Chenhui Ji, Guanglai Li, Christian Hölscher. Eur J Pharmacol 2017
51
43

Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Peng Feng, Xiangjian Zhang, Dongfang Li, Chenhui Ji, Ziyue Yuan, Ruifang Wang, Guofang Xue, Guanglai Li, Christian Hölscher. Neuropharmacology 2018
52
40


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
20

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.
A Hamilton, S Patterson, D Porter, V A Gault, C Holscher. J Neurosci Res 2011
150
19

Parkinson's disease, insulin resistance and novel agents of neuroprotection.
Iciar Aviles-Olmos, Patricia Limousin, Andrew Lees, Thomas Foltynie. Brain 2013
185
19

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
Dilan Athauda, Seema Gulyani, Hanuma Kumar Karnati, Yazhou Li, David Tweedie, Maja Mustapic, Sahil Chawla, Kashfia Chowdhury, Simon S Skene, Nigel H Greig,[...]. JAMA Neurol 2019
94
20

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.
Abba J Kastin, Victoria Akerstrom, Weihong Pan. J Mol Neurosci 2002
343
18



Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
811
18


An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
576
17

Type 2 diabetes and the risk of Parkinson's disease.
Gang Hu, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen, Jaakko Tuomilehto. Diabetes Care 2007
289
17

A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Dong Seok Kim, Ho-Il Choi, Yun Wang, Yu Luo, Barry J Hoffer, Nigel H Greig. Cell Transplant 2017
72
23

GLP-1 secretion by microglial cells and decreased CNS expression in obesity.
Camilla Kappe, Linda M Tracy, Cesare Patrone, Kerstin Iverfeldt, Åke Sjöholm. J Neuroinflammation 2012
62
25


Entry of exendin-4 into brain is rapid but may be limited at high doses.
A J Kastin, V Akerstrom. Int J Obes Relat Metab Disord 2003
254
16

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
TracyAnn Perry, Norman J Haughey, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
264
16



Incretin-based therapies for type 2 diabetes mellitus.
Julie A Lovshin, Daniel J Drucker. Nat Rev Endocrinol 2009
492
15

Insulin resistance impairs nigrostriatal dopamine function.
J K Morris, G L Bomhoff, B K Gorres, V A Davis, J Kim, P-P Lee, W M Brooks, G A Gerhardt, P C Geiger, J A Stanford. Exp Neurol 2011
91
16

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Chenhui Ji, Guo-Fang Xue, Cao Lijun, Peng Feng, Dongfang Li, Lin Li, Guanglai Li, Christian Hölscher. Brain Res 2016
60
25

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
Lijun Cao, Dongfang Li, Peng Feng, Lin Li, Guo-Fang Xue, Guanglai Li, Christian Hölscher. Neuroreport 2016
48
31

Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
137
15

Parkinson's disease.
Lorraine V Kalia, Anthony E Lang. Lancet 2015
15

Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.
Takashi Iwai, Satoshi Ito, Kahori Tanimitsu, Shunichi Udagawa, Jun-Ichiro Oka. Neurosci Res 2006
147
14

Saxagliptin: a novel antiparkinsonian approach.
Noha N Nassar, Muhammad Y Al-Shorbagy, Hany H Arab, Dalaal M Abdallah. Neuropharmacology 2015
59
23



Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice.
Lital Rachmany, David Tweedie, Yazhou Li, Vardit Rubovitch, Harold W Holloway, Jonathan Miller, Barry J Hoffer, Nigel H Greig, Chaim G Pick. Age (Dordr) 2013
69
20


Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
319
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.